Equities

Mediwound Ltd

Mediwound Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)17.72
  • Today's Change0.150 / 0.85%
  • Shares traded45.91k
  • 1 Year change+89.72%
  • Beta0.8392
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Mediwound Ltd had revenues fall -29.48% from 26.50m to 18.69m, though the company grew net income from a loss of 19.60m to a smaller loss of 6.72m.
Gross margin13.25%
Net profit margin-99.17%
Operating margin-75.16%
Return on assets-32.83%
Return on equity-75.66%
Return on investment-49.28%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Mediwound Ltd fell by 22.03m. Cash Flow from Financing totalled 22.92m or 122.64% of revenues. In addition the company used 10.47m for operations while cash used for investing totalled 34.32m.
Cash flow per share-2.01
Price/Cash flow per share--
Book value per share1.92
Tangible book value per share1.91
More ▼

Balance sheet in USDView more

Mediwound Ltd has a Debt to Total Capital ratio of 26.23%, a higher figure than the previous year's 1.94%.
Current ratio1.65
Quick ratio1.51
Total debt/total equity0.3556
Total debt/total capital0.2623
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items increased 81.04%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago
10.00
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.